Patents by Inventor Søren Moestrup

Søren Moestrup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF PROGNOSIS
    Publication number: 20150093765
    Abstract: The present invention relates to the use of soluble CD163 as a prognostic marker for the assessment of the risk for contracting a disorder, in particular for contracting diabetes and/or a liver disorder. The invention also relates to the use of CD163 as a prognostic marker for assessing lifetime expectancy.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 2, 2015
    Inventors: Søren Moestrup, Ruth Frikke-Schmidt, Anne Tybjaerg-Hansen, Holger J. Moller
  • METHOD OF PROGNOSIS
    Publication number: 20120252041
    Abstract: The present invention relates to the use of soluble CD163 as a prognostic marker for the assessment of the risk for contracting a disorder, in particular for contracting diabetes and/or a liver disorder. The invention also relates to the use of CD163 as a prognostic marker for assessing lifetime expectancy.
    Type: Application
    Filed: October 12, 2010
    Publication date: October 4, 2012
    Applicants: Region Midjylland, Aarhus Universitet
    Inventors: Søren Moestrup, Ruth Frikke-Schmidt, Anne Tybjaerg-Hansen, Holger J. Møller
  • Apolipoprotein analogues
    Patent number: 6897039
    Abstract: The invention relates to a pharmaceutical composition comprising an apolipoprotein construct, to an apolipoprotein construct, a nucleic acid sequence encoding the apolipoprotein construct, a vector comprising the nucleic acid sequence, a method for producing the apolipoprotein construct, and a method of treatment comprising administering the apolipoprotein construct. The presented data document that the constructs according to the invention are capable of binding lipids, are capable of binding cubilin, which is a strong Apo AI receptor, stronger than native Apo A-I and that the plasma half life of the constructs is at least tripled compared to native Apo A-I. Together these data document that the constructs according to the invention are strong candidates for treatment of cardiovascular diseases.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: May 24, 2005
    Assignee: ProteoPharma Aps
    Inventors: Jonas Graversen, Søren Moestrup